Palbociclib trials for Breast cancer

All Palbociclib trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Palbociclib for Breast cancer

• A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
  NCT06188520 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 14 locations
• A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
  NCT06997029 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
  NCT05766410 · Phase: Phase 2 · Ages: 20 Years and older · Sex: Female · 2 locations
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
  NCT04802759 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 32 locations
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
  NCT06856200 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 359 locations
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 352 locations
• A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
  NCT07347600 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
  NCT05683418 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 18 locations
• Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
  NCT04841148 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
  NCT07492641 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
  NCT05768139 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 65 locations
• Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
  NCT06805812 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
  NCT06380751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 302 locations
• Study of AVZO-021 in Patients With Advanced Solid Tumors
  NCT05867251 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Study of PF-07248144 in Advanced or Metastatic Solid Tumors
  NCT04606446 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 132 locations
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
  NCT05564377 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 482 locations
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
  NCT06377852 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · 73 locations

Common questions

How many trials study Palbociclib for Breast cancer?

19 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.